- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00286273
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration, a Randomized Controlled Trial Comparing Anticoagulation With Citrate to the Low Molecular Weight Heparin Nadroparin
Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. To bridge the period to recovery, renal function is temporarily replaced by continuous venovenous hemofiltration (CVVH). To prevent clotting of the hemofiltration circuit, heparin is generally used, providing anticoagulation in the circuit and the patient. As a result, bleeding complications may occur, necessitating the transfusion of blood. Anticoagulation of the circuit can also be obtained with the use of tri-sodium citrate, which provides anticoagulation of the circuit without affecting coagulation in the patient and thus without increasing his/her risk of bleeding. The use of citrate may however cause metabolic complications.
Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Severely ill patients admitted to the intensive care unit may develop an acute failure of kidney function. Renal function generally recovers if the acute illness improves. To bridge this period, renal function is temporarily replaced by continuous hemofiltration, so called continuous venovenous hemofiltration (CVVH). To remove toxic substances and fluids, the patient's blood flows through a circuit, containing a filter. Flow in the filter is regulated by the CVVH-device.
Normally blood starts to clot as soon as it leaves the body. To prevent clotting of the blood in the filter, the blood has to be 'anticoagulated'. For this purpose, heparins are generally used. Heparins make the blood less likely to clot. Drawback of the use of heparins is that they not only prevent clotting of blood in the circuit and the filter, but also in the patient. Heparins thereby increase the risk of bleeding. Intensive care patients are at higher risk of bleeding due to a recent operation or trauma, ulcers in the mouth or the stomach, or abnormalities in their blood to the acute illness. Due to the continuous application of CVVH for days, anticoagulation is administered without interruption over prolonged periods of time. Studies report bleeding complications in 5 to 50% of the patients. As a result of bleeding, patients need blood transfusion and sometimes surgery. Control of bleeding is sometimes extremely difficult.
An alternative to heparin is citrate, which allows regional anticoagulation of the circuit and the filter without an effect increasing the risk of bleeding for the patient. Anticoagulation with citrate is more complex, nurses need to follow a strict protocol.. Several small studies have shown that regional anticoagulation with citrate is associated with less bleeding and a longer filter survival. The use if citrate is however associated with a greater risk of metabolic complications, if the protocol is not strictly followed. Primary aim of the present study is to show in a larger group of intensive care patients whether the use of regional anticoagulation with citrate is safe compared to systemic anticoagulation with the low molecular weight heparin nadroparin.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1090HM
- Onze Lieve Vrouwe Gasthuis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Intensive care patients scheduled for continuous venovenous hemofiltration
Exclusion Criteria:
- Severe pre-existent liver failure (cirrhosis Child C), acute liver dysfunction as occurring with septic shock is not a reason for exclusion
- Active bleeding or bleeding necessitating the infusion of two red blood cell units within 24 hours before starting hemofiltration or a fall in hemoglobin of > 0.5 mmol/l. A fall in hemoglobin/hematocrit as a result of fluid loading is not regarded as bleeding.
- Surgery within 24 h prior to CVVH.
- Patients needing full systemic anticoagulation (unfractionated heparin in a dose of > 10000 IU/day, or nadroparin > 3800 IU/day) for other reasons
- Expectation to die within 24 hours
- Chronic dialysis
- Proven or suspected heparin-induced thrombocytopenia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: citrate
regional anticoagulation with citrate
|
for regional anticoagulation of the extracorporeal CVVH circuit
Other Names:
|
ACTIVE_COMPARATOR: nadroparin
nadroparin is a low molecular weight heparin
|
for anticoagulation of the extracorporeal CVVH circuit
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
bleeding complications
Time Frame: during administration of study anticoagulant
|
during administration of study anticoagulant
|
transfusion requirement
Time Frame: during administration of study anticoagulant
|
during administration of study anticoagulant
|
filter survival
Time Frame: during hemofiltration
|
during hemofiltration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
mortality
Time Frame: 3-month and hospital admission
|
3-month and hospital admission
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Heleen M Oudemans-van Straaten, MD,PhD, Onze Lieve Vrouwe Gasthuis
Publications and helpful links
General Publications
- Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, Kataoka Y. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012467. doi: 10.1002/14651858.CD012467.pub3.
- Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009 Feb;37(2):545-52. doi: 10.1097/CCM.0b013e3181953c5e.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency
- Acute Kidney Injury
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Anticoagulants
- Chelating Agents
- Sequestering Agents
- Calcium Chelating Agents
- Heparin
- Heparin, Low-Molecular-Weight
- Tinzaparin
- Dalteparin
- Citric Acid
- Sodium Citrate
- Nadroparin
Other Study ID Numbers
- WON 03.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Acute
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Clinica Universidad de Navarra, Universidad de...CompletedKIDNEY FAILURE, ACUTESpain
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
Medical University of GdanskTerminatedAcute Renal FailurePoland
-
Tarek M. El-AchkarSatellite Healthcare; Triax PharmaceuticalsCompletedKidney Failure, Acute | Acute Kidney InsufficiencyUnited States
-
Nantes University HospitalCompletedAcute Renal Failure | Chronic Kidney Failure | Acute Kidney Tubular Necrosis
-
Baxter Healthcare CorporationRecruitingAcute Kidney Failure | Chronic Kidney FailureChina
-
University Hospital, Clermont-FerrandRecruitingAcute Kidney Injury | Transient Acute Renal Failure | Persistent Acute Renal FailureFrance
-
Wake Forest University Health SciencesCompletedRenal Replacement Therapy | Kidney Failure, AcuteUnited States
-
Wroclaw Medical UniversityCompleted
Clinical Trials on trisodium citrate
-
Erasme University HospitalCompletedOther Complication of Vascular Dialysis CatheterBelgium
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAtherosclerosis | Intermittent Claudication | Peripheral Artery Disease | Chronic Total Aterial OcclusionUnited States
-
University of EdinburghUnknownDilated Cardiomyopathy | Hypertrophic Cardiomyopathy | Ischemic CardiomyopathyUnited Kingdom
-
Hospital Israelita Albert EinsteinRecruitingAcute Kidney InjuryBrazil
-
Marija Malgaj VrečkoActive, not recruitingEnd Stage Renal Disease | Anticoagulation | HaemodialysisSlovenia
-
Catholic University of PelotasCompletedCatheter Related Infection
-
Bachir TaouliCompletedChronic Liver DiseaseUnited States
-
Maastricht University Medical CenterWithdrawnOvarian NeoplasmsNetherlands
-
Sunnybrook Health Sciences CentreUnknownCancer | Liver Neoplasms | MetastasesCanada
-
Maastricht University Medical CenterDutch Cancer SocietyCompletedRectal Neoplasms | Magnetic Resonance Imaging | Neoplasms StagingNetherlands